Cytosorbents Crp (CTSO)

Cytosorbents Corporation is a healthcare company focused on the research, development, and commercialization of medical devices based on its blood purification platform. The company’s technology uses a proprietary adsorbent and porous polymer approach and is applied in the United States, Germany, and other international markets. Its product portfolio includes CytoSorb, an extracorporeal blood purification cartridge used in settings involving severe inflammation, organ failure, cardiothoracic surgery, sepsis, and related complications; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a blood purification adsorber for veterinary applications; PuriFi, an advanced hemoperfusion pump; and ECOS-300CY, an ex vivo organ perfusion system. Cytosorbents also develops HemoDefend-BGA, a platform designed to reduce anti-A and anti-B antibodies in plasma and whole blood. Founded in 1997 and headquartered in Princeton, New Jersey, the company was previously known as MedaSorb Technologies Corporation before adopting its current name in 2010.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.